靶向治疗高危胃肠道间质瘤的临床疗效

目的:探讨应用伊马替尼治疗高危胃肠道间质瘤(GIST)的临床疗效。方法:回顾性分析2010年1月—2015年6月收治的56例接受伊马替尼靶向治疗的高危GIST患者临床资料,并对疗效进行分析。结果:19例无手术切除机会的患者经伊马替尼(400 mg/d)治疗6~8个月后,无完全缓解(CR)者,部分缓解(PR)14例,疾病稳定(SD)4例,疾病进展(PD)1例;7例(36.8%)PR患者获得手术切除机会。35例行手术切除后服用伊马替尼(400 mg/d)1年,随访3例复发,1年复发率8.6%;2例终断服药,无法评估疗效。结论:伊马替尼治疗GIST疗效肯定,对于高危GIST患者,术前新辅助化疗能让无法手术切除的肿瘤获得手术机会,术后辅助化疗可能提高无瘤生存率,不良反应较轻能够耐受。

Clinical effect of imatinib targeted therapy on high risk gastrointestinal stromal tumor

Objective: To explore the clinical effect of imatinib targeted therapy on high risk gastrointestinal stromal tumor (GISTS).Methods: The clinical data of 56 patients with high risk GIST undergoing imatinib targeted therapy from January 2010 to June 2015 were reviewed, and the therapeutic efficacy was analyzed.Results: Nineteen patients, who had no chance of surgical resection, received imatinib (400 mg/d) therapy for 6 to 8 months, and of them, none achieved complete response (CR), 14 cases obtained partial response (PR), 4 cases had stable disease (SD), and one case presented progressive disease (PD); 7 PR cases (36.8%) obtained a chance for tumor resection. Thirty-five patients received imtinib (400 mg/d) treatment for one year after surgical resection, and of them, recurrence occurred in 3 cases (8.6%) during follow-up and the one-year recurrence rate was 8.6%; 2 cases did not continue to take the medication and their results could not be determined. Conclusion: Imatinib has significant efficacy in GIST patients, and in those with high risk GIST, its preoperative neoadjuvant chemotherapy may offer a chance of surgical resection for the unresectable tumors, and its postoperative adjuvant chemotherapy may improve the tumor-free survival with tolerable adverse effects.